Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.
The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans
Mastering compliance and copyright in healthcare and MedComms
AstraZeneca director says AI must be a “thought partner” in drug discovery